Yes, genetic factors can influence the susceptibility to pyrazinoic acid-induced toxicity. Genetic polymorphisms in enzymes responsible for drug metabolism, such as NAT2 acetyltransferase, can affect the rate of pyrazinamide and pyrazinoic acid clearance. Individuals with certain genetic variants may be at increased risk for hepatotoxicity, highlighting the importance of personalized medicine approaches in tuberculosis treatment.
